Xuan Dong's research while affiliated with Government of the People's Republic of China and other places

Publications (17)

Article
Background: To date, there is no effective medicine to treat coronavirus disease 2019 (COVID-19), and the antiviral efficacy of arbidol in the treatment for COVID-19 remained equivocal and controversial. The purpose of this study was to evaluate the efficacy and safety of arbidol tablets in the treatment of COVID-19. Methods: This was a prospect...
Article
Full-text available
Background: Systemic reactivation of Epstein-Barr virus (EBV) may occur in novel coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). However, the clinical consequences of EBV reactivation remain uncertain. Methods: In this retrospective study, we screened 1314 patients with confirmed CO...
Preprint
Full-text available
Background. The impact of corticosteroids on severe patients with coronavirus disease 2019 (COVID-19)/ chronic hepatitis B virus (HBV) co-infection is currently unknown. We aimed to investigate effect of corticosteroid on these subgroup patients. Methods. In this retrospective multicenter study including 5447 confirmed COVID-19 patients from Jan 1,...
Article
Full-text available
Background: Thymosin alpha 1 (Tα1) is widely used to treat patients with COVID-19 in China; however, its efficacy remains unclear. This study aimed to explore the efficacy of Tα1 as a COVID-19 therapy. Methods: We performed a multicenter cohort study in five tertiary hospitals in the Hubei province of China between December 2019 and March 2020....
Article
Background Novel coronavirus disease 2019 (COVID-19) is an ongoing global pandemic with high mortality. Although several studies have reported different risk factors for mortality in patients based on traditional analytics, few studies have used artificial intelligence (AI) algorithms. This study investigated prognostic factors for COVID-19 patient...
Article
Full-text available
Background Secondary hemophagocytic lymphohistiocytosis (sHLH) is a life-threatening hyperinflammatory event and a fatal complication of viral infections. Whether sHLH may also be observed in patients with a cytokine storm induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is still uncertain. We aimed to determine the...
Article
Full-text available
Background: Since December 2019, an outbreak of Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) initially emerged in Wuhan, China, and has spread worldwide now. Clinical features of patients with COVID-19 have been described. However, risk factors leading to in-hospital deterioration a...
Article
BACKGROUND Corticosteroids are widely used in patients with COVID 19, although their benefit-to-risk ratio remains controversial.METHODS Patients with severe COVID-19-related acute respiratory distress syndrome (ARDS) were included from December 29, 2019 to March 16, 2020 in 5 tertiary Chinese hospitals. Cox proportional hazards and competing risks...
Article
Full-text available
Purpose: To predict the risk of developing severe pneumonia among mild novel coronavirus pneumonia (mNCP) patients on admission. Methods: A retrospective cohort study was conducted at three hospitals in Shanghai and Wuhan from January 2020 to February 2020. Real-time polymerasechain-reaction assays were used to detect COVID-19. A total of 529 pa...
Article
Background: The outbreak of COVID-19 caused by SARS-CoV-2 has been a pandemic. The objective of our study was to explore the association between sex and clinical outcomes in patients with COVID-19. Methods: Detailed clinical data including clinical characteristics, laboratory tests, imaging features and treatments of 1190 cases of adult patients...
Preprint
Full-text available
Background: Intravenous immunoglobulin (IVIG) is commonly used to treat severe COVID-19, although the clinical outcomes remain unclear. This study evaluated the effectiveness of IVIG treatment for severe COVID-19. Methods: This retrospective multi-center study evaluated 28-day mortality and time for SARS-CoV-2 RNA clearance in severe COVID-19 patie...
Article
Background Coronavirus disease 2019 (COVID‐19) emerged in Dec 2019 and has spread globally. Diabetics are at increased risk of infections caused by a variety of pathogens including virus. The present research was aimed to describe clinical characteristics and outcomes of COVID‐19 patients with diabetes. Methods A retrospective multicenter study of...
Article
Background: No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2. Methods: We conducted a randomized, controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2 infection, which causes the respiratory illness Covid-19, and an oxygen saturation (Sao2) of 94% or l...
Article
Background: In December, 2019, a pneumonia associated with the 2019 novel coronavirus (2019-nCoV) emerged in Wuhan, China. We aimed to further clarify the epidemiological and clinical characteristics of 2019-nCoV pneumonia. Methods: In this retrospective, single-centre study, we included all confirmed cases of 2019-nCoV in Wuhan Jinyintan Hospit...

Citations

... Recently, a few cases of CMV reactivation in the setting of severe COVID-19 have been reported [16][17][18][19]. Intriguingly, also reactivation of EBV and Herpes simplex virus (HSV) have been described [20][21][22][23], indicating that these latent herpesvirus infections may further contribute to the development of severe COVID-19. However, it remains to elucidate whether herpesvirus reactivations are a direct consequence of SARS-CoV-2 infections or of the treatments related to COVID-19 (for example steroids), and whether they affect the same category of patients. ...
... the reason for this significant difference could be the fact that although the baseline characters were similar in the two group but the patients included in the thymosin group had slightly larger proportion of critically ill patients. 7 In other study by YuepingLui et al, a significant mortality benefit was seen in patients who received thymosin alpha with a p value of 0.04. however, the benefit was more in patients with CD8+ count of < 400/microL and CD4+ count <650/microL. ...
... Zhang et al. [55] analyzed the clinical features and outcome of different positive COVID-19 where nine mortality factors are identified utilizing a least absolute shrinkage and selection operator regression technique that are then tested by an artificial neural network algorithm. ...
... Recent studies show that the cytokine storm induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has significant similarities to clinical and laboratory findings of sHLH (Kim et al. 2021;Meng et al. 2021;Mehta et al. 2020;Tsatsakis et al. 2020;Stancioiu et al. 2020;Kostoff et al. 2022). SARS-CoV-2 belongs to the family of Coronaviridae and causes COVID-19 disease, which is a respiratory illness (Tsatsakis et al. 2020;Wang et al. 2020;Wu and McGoogan 2020). ...
... Forty-six studies (48.4%) [28,83,84,86,90,91,96,98,100,101,104,[107][108][109][110]112,[115][116][117][120][121][122]124,130,132,135,137,139,141,[143][144][145]150,151,154,[156][157][158]164,165,[168][169][170]172,173] included all hospitalized COVID-19 patients, 20 studies (21.1%) [87,93,97,99,102,103,126,131,133,134,136,138,142,146,147,152,155,160,163,174] only included hospitalized patients with severe disease, while 6 studies (6.3%) [88,92,106,111,119,128] included hospitalized patients without severe disease. Last, 22 studies (23.2%) [ pitalized patients, and 1 study (1.1%) [166] only included hospitalized patients receiving mechanical ventilation. ...
... 31 On the contrary, similar Several studies have shown a higher risk of complications and death from COVID-19 in patients with diabetes mellitus, hypertension, and severe obesity. [10][11][12][13][14][15][16][17][18][19] Similar to our results, smoking history has been shown to increase disease severity and mortality, with a hazard ratio of 1.4-2.4 times. ...
... The prevalence of AKI in COVID-19 has been variably reported from centres across the world. Early studies from China estimated the prevalence of AKI to be between 0.5 and 7% [11][12][13][14][15]. A much higher prevalence varying between 28 and 45% was seen in large-scale studies from other parts of the world [16][17][18]. ...
... We gratefully acknowledge helpful conversations with Cynthia Magro and Jerry Nuovo. severe COVID-19 (141). The need for evaluation of potential interventions is of growing concern as new data suggest that the risk of severe outcomes in acute COVID-19, and the risk for development of long COVID, increases in a graded fashion according to the number of SARS-CoV-2 infections experienced, regardless of vaccination status (142). ...
... Zhu et al. [10] found that patients with diabetes needed more medical interventions and had more frequent multiple organ injury events than patients without diabetes. Huahua et al. [11] found that patients with diabetes and COVID-19 developed more severe disease, had more complications (such as ARDS and AKI), required ICU admission more often, and had higher mortality than patients without diabetes. Sardu et al. [12] also support similar findings. ...
... The COVID-19 disease caused by the coronavirus 2 (SARS-CoV-2) was first identified in 43 December 2019 in Wuhan, China(Lu et al. 2020;Xu et al. 2020). It quickly spread throughout 44 China and other countries in the following months, becoming a global public health concern 45 (Chen et al. 2020a; Chen et al. 2020b;Chen and Li 2020;Gilbert et al. 2020;Li et al. 2020;46 Sohrabi et al. 2020). In general, most people with SARS-CoV-2 have mild symptoms such as 47 fever, dry cough, and sore throat (Huang et al. 2020;Sohrabi et al. 2020). ...